SCHEDULE: ARK Investment Management Confirms Beam Therapeutics Stake

ARK Investment Management LLC and Catherine D. Wood have filed an amendment to their Schedule 13G, confirming their beneficial ownership of 9.95% of Beam Therapeutics Inc. common stock as of June 30, 2026.

Summary

• This filing is an Amendment No. 7 to a Schedule 13G, jointly filed by ARK Investment Management LLC and Catherine D. Wood.
• The filing confirms their beneficial ownership of Beam Therapeutics Inc. common stock as of June 30, 2026.
• The aggregate amount beneficially owned by both ARK Investment Management LLC and Catherine D. Wood is 10,234,862 shares.
• This ownership represents 9.95% of the class of securities.
• The filing serves to update and confirm previous disclosures regarding their holdings.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily administrative in nature, confirming existing beneficial ownership levels without significant new information.

Positives

• Confirmation of continued significant investment by ARK Investment Management and Catherine D. Wood in Beam Therapeutics.
• The ownership stake of 9.95% indicates a substantial interest and potential influence.
• The filing is an administrative update, suggesting no adverse changes in their investment strategy or holdings.

Negatives

• No new positive developments or strategic shifts are disclosed in this administrative filing.
• The filing does not provide any new information regarding Beam Therapeutics' operational performance or future prospects.

Risks

• The filing itself does not introduce new risks, but the underlying investment in Beam Therapeutics is subject to the company's own business and market risks.
• Changes in ARK's investment strategy or regulatory changes could impact future filings and ownership levels.

Future Outlook

This filing is an amendment to a Schedule 13G and does not contain forward-looking statements or specific future guidance from Beam Therapeutics Inc. It only confirms current beneficial ownership levels.

Management Comments

• ARK Investment Management LLC and Catherine D. Wood agree to file an Amendment No. 7 to the Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer.
• They further agree that said Amendment No. 7 shall be filed on behalf of each of them.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure under SEC regulations for significant beneficial ownership. It confirms ARK's continued substantial investment in Beam Therapeutics, a company operating in the biotechnology sector, which is characterized by high R&D costs and potential for significant breakthroughs or setbacks.

Stakeholder Impact

• Shareholders: The confirmation of ARK's significant stake may be viewed positively, indicating continued institutional support, but the filing itself does not directly impact share price without new information.
• Management of Beam Therapeutics: The filing confirms a major shareholder's continued interest, which can be a signal of confidence.
• Regulators: Ensures compliance with SEC disclosure requirements regarding beneficial ownership.

Next Steps

• ARK Investment Management LLC and Catherine D. Wood will continue to hold their beneficial ownership in Beam Therapeutics Inc.
• Future amendments to the Schedule 13G will be filed if there are material changes in beneficial ownership.

Key Dates

Keywords

Beam Therapeutics, ARK Investment Management, Catherine D. Wood, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Amendment